AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 18.2261
- Book/Share 14.4548
- PB 5.1347
- Debt/Equity 0.7343
- CurrentRatio 0.8629
- ROIC 0.1094
- MktCap 229652206656.0
- FreeCF/Share 2.8142
- PFCF 26.3242
- PE 27.6814
- Debt/Assets 0.2921
- DivYield 0.0211
- ROE 0.1984
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
AstraZeneca: Great Portfolio, But Not A Great Price
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive
AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and Ultomiris show impressive growth, but looming patent expiries and legal risks threaten future revenues. Heavy R&D investment and strategic moves into cell/gene therapy and AI-driven drug discovery support AstraZeneca's long-term growth outlook.
Read More
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
Read More
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
3 Of The Best SWANs On My Shopping List
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Positive
Our picks for today are MercadoLibre, Vulcan Materials, and AstraZeneca, with each providing a mix of value and growth. MercadoLibre is Latin America's leading e-commerce and fintech platform with increasing e-commerce penetration rates and economic growth driving its macro growth story. Vulcan Materials is the largest U.S. producer of construction aggregates, making it a beneficiary of U.S. infrastructure spending.
Read More
Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana
Published: July 30, 2025 by: Business Wire
Sentiment: Neutral
ACCRA, Ghana--(BUSINESS WIRE)-- #AfricaHealth--The strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial announcement in April 2025, the collaboration has made remarkable progress in improving the patient journey—from early diagnosis to molecular testing and now, access to life-saving treatment. In a landmark development, AstraZeneca launched one of their targeted therapies for EGFR mutated Lung Cancer patients in G.
Read More
AstraZeneca gets clean bill of health from leading investment bank
Published: July 30, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) shares have caught the attention of UBS, which reiterated its 'buy' rating and raised its price target to 14,200p, implying over 27% upside from the current level, after a solid set of second-quarter results. The drugmaker beat the Swiss Bank's estimates on both sales and operating profit, helped by stronger-than-expected growth in US oncology and a rebound in its rare disease division.
Read More
AstraZeneca PLC (AZN) Q2 2025 Earnings Call Transcript
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
AstraZeneca PLC (NASDAQ:AZN ) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Andrew P. Barnett - Head of Investor Relations Aradhana Sarin - CFO & Executive Director David Fredrickson - Executive Vice-President of Oncology Haematology Business Unit Iskra Reic - Executive Vice President of International Marc Dunoyer - CEO of Alexion & Chief Strategy Officer Pascal Claude Roland Soriot - CEO & Executive Director Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D Susan Mary Galbraith - Executive Vice President of Oncology R&D Conference Call Participants Gonzalo …
Read More
AstraZeneca CEO: Medical innovation in China is surging
Published: July 29, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
"What we have seen in China is really, a substantial return of scientists from the US, but also from the UK and elsewhere, but not because of policy, simply because they could see opportunities in China," says AstraZeneca CEO Pascal Soriot https://bloom.bg/3UAuNVP
Read More
AstraZeneca CEO: If you manufacture locally, there's no need to increase prices
Published: July 29, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Sara Eisen talks with AstraZeneca Pascal Soriot CEO to discuss the company's most recent quarter, investment in innovation in the U.S., whether tariffs could impact prices, and much more.
Read More
AstraZeneca gets £3.3bn lift after upbeat results and steady outlook
Published: July 29, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) saw £3.3 billion added to its market value after delivering a strong set of half-year results and confirming its guidance for 2025. The group reported second-quarter revenue of $14.46 billion, up 12%, driven by double-digit gains in oncology and biopharmaceuticals.
Read More
Astrazeneca (AZN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
AZN's second-quarter revenues beat on strong drug sales across Oncology and CVRM despite in-line earnings.
Read More
AstraZeneca Stock Rises as US, Cancer Drug Growth Lifts Q2 Results
Published: July 29, 2025 by: Investopedia
Sentiment: Positive
AstraZeneca (AZN) shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates on strong U.S. growth and demand for its cancer drugs.
Read More
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Read More
Insights Into Astrazeneca (AZN) Q2: Wall Street Projections for Key Metrics
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
5 Ideal "Safer" Dividend Buys From Bloomberg's July Watch List
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
Bloomberg's 50 Companies to Watch leverages catalysts like new leadership, AI, and policy shifts to identify high-potential stocks for 2025. Yield-based 'dogcatcher' analysis spotlights 15 dividend payers with strong free cash flow, with five 'IDEAL' stocks signaling safer, buy-worthy dividends. Top ten dividend focus stocks project an average 16.69% net gain by July 2026, with risk profiles generally below market averages.
Read More
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
Published: July 22, 2025 by: Fast Company
Sentiment: Positive
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy.
Read More
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.
Read More
AstraZeneca to invest $50B in US to boost drug manufacturing and R&D
Published: July 22, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) has announced plans to invest $50 billion in the United States by 2030, marking the pharmaceutical giant's largest-ever investment in a single market. The UK-headquartered biopharmaceutical company said the investment will expand its domestic manufacturing and research footprint as it works toward a long-term revenue target of $80 billion annually, with half of that total expected to come from the US market.
Read More
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
Read More
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
Read More
AstraZeneca shares show signs of life after successful trials of hypertension drug
Published: July 14, 2025 by: Market Watch
Sentiment: Positive
Baxdostat trials showed immense promise for huge available market.
Read More
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generall.
Read More
AstraZeneca drug lowers high BP in late-stage study; shares rise
Published: July 14, 2025 by: Reuters
Sentiment: Positive
AstraZeneca 's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of people whose condition was hard to control or treat, the Anglo-Swedish drugmaker said on Monday, sending shares up 2%.
Read More
Trumps 200% tariffs. Here's what it means for UK pharma investors
Published: July 10, 2025 by: Proactive Investors
Sentiment: Negative
UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive concerns over protectionist policies targeting medicines not manufactured on American soil.
Read More
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
Published: July 09, 2025 by: Proactive Investors
Sentiment: Positive
If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN) should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pipeline readouts that haven't yet made their way into the share price.
Read More
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales.
Read More
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
Read More
Why AstraZeneca Stock Got Thumped on Thursday
Published: July 03, 2025 by: The Motley Fool
Sentiment: Positive
AstraZeneca (AZN -2.36%) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300